|
1
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tahir N, Mahboob A, Piao X, Ying G,
Shrestha J, Sherchan R and Zahra F: Nivolumab, a Double-Edged
Sword: A case report of nivolumab-induced myasthenia gravis. J Med
Cases. 12:424–428. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Wilgenhof S and Neyns B: Anti-CTLA-4
antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann
Oncol. 22:991–993. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kao JC, Liao B, Markovic SN, Klein CJ,
Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H
and Mauermann ML: Neurological complications associated with
anti-programmed death 1 (PD-1) antibodies. JAMA Neurol.
74:1216–1222. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hottinger AF: Neurologic complications of
immune checkpoint inhibitors. Curr Opin Neurol. 29:806–812.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Haugh AM, Probasco JC and Johnson DB:
Neurologic complications of immune checkpoint inhibitors. Expert
Opin Drug Saf. 19:479–488. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Safa H, Johnson DH, Trinh VA, Rodgers TE,
Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, et
al: Immune checkpoint inhibitor related myasthenia gravis: Single
center experience and systematic review of the literature. J
Immunother Cancer. 7(319)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Weaver JM, Dodd K, Knight T, Chaudhri M,
Khera R, Lilleker JB, Roberts M, Lorigan P and Cooksley T: Improved
outcomes with early immunosuppression in patients with
immune-checkpoint inhibitor induced myasthenia gravis, myocarditis
and myositis: A case series. Support Care Cancer.
31(518)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Grob D, Brunner N, Namba T and Pagala M:
Lifetime course of myasthenia gravis. Muscle Nerve. 37:141–149.
2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gummi RR, Kukulka NA, Deroche CB and
Govindarajan R: Factors associated with acute exacerbations of
myasthenia gravis. Muscle Nerve. 60:693–699. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suzuki S, Utsugisawa K, Yoshikawa H,
Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T,
Sato H, et al: Autoimmune targets of heart and skeletal muscles in
myasthenia gravis. Arch Neurol. 66:1334–1338. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kang KH, Grubb W, Sawlani K, Gibson MK,
Hoimes CJ, Rogers LR, Lavertu P and Yao M: Immune
checkpoint-mediated myositis and myasthenia gravis: A case report
and review of evaluation and management. Am J Otolaryngol.
39:642–645. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kao JC, Brickshawana A and Liewluck T:
Neuromuscular complications of programmed cell death-1 (PD-1)
Inhibitors. Curr Neurol Neurosci Rep. 18(63)2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kimura T, Fukushima S, Miyashita A, Aoi J,
Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, et
al: Myasthenic crisis and polymyositis induced by one dose of
nivolumab. Cancer Sci. 107:1055–1058. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen YH, Liu FC, Hsu CH and Chian CF:
Nivolumab-induced myasthenia gravis in a patient with squamous cell
lung carcinoma: Case report. Medicine (Baltimore).
96(e7350)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fazel M and Jedlowski PM: Severe myositis,
myocarditis, and myasthenia gravis with elevated anti-striated
muscle antibody following single dose of ipilimumab-nivolumab
therapy in a patient with metastatic melanoma. Case Reports
Immunol. 2019(2539493)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liao B, Shroff S, Kamiya-Matsuoka C and
Tummala S: Atypical neurological complications of ipilimumab
therapy in patients with metastatic melanoma. Neuro Oncol.
16:589–593. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Johnson DB, Saranga-Perry V, Lavin PJ,
Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA,
Kudchadkar RR and Sosman JA: Myasthenia gravis induced by
ipilimumab in patients with metastatic melanoma. J Clin Oncol.
33:e122–e124. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Loochtan AI, Nickolich MS and Hobson-Webb
LD: Myasthenia gravis associated with ipilimumab and nivolumab in
the treatment of small cell lung cancer. Muscle Nerve. 52:307–308.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Maeda O, Yokota K, Atsuta N, Katsuno M,
Akiyama M and Ando Y: Nivolumab for the treatment of malignant
melanoma in a patient with pre-existing myasthenia gravis. Nagoya J
Med Sci. 78:119–122. 2016.PubMed/NCBI
|
|
21
|
Sciacca G, Nicoletti A, Rampello L, Noto
L, Parra HJ and Zappia M: Benign form of myasthenia gravis after
nivolumab treatment. Muscle Nerve. 54:507–509. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shirai T, Sano T, Kamijo F, Saito N,
Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R and Uhara H:
Acetylcholine receptor binding antibody-associated myasthenia
gravis and rhabdomyolysis induced by nivolumab in a patient with
melanoma. Jpn J Clin Oncol. 46:86–88. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Polat P and Donofrio PD: Myasthenia gravis
induced by nivolumab therapy in a patient with non-small-cell lung
cancer. Muscle Nerve. 54(507)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chang E, Sabichi AL and Sada YH:
Myasthenia gravis after nivolumab therapy for squamous cell
carcinoma of the bladder. J Immunother. 40:114–116. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen JH, Lee KY, Hu CJ and Chung CC:
Coexisting myasthenia gravis, myositis, and polyneuropathy induced
by ipilimumab and nivolumab in a patient with non-small-cell lung
cancer: A case report and literature review. Medicine (Baltimore).
96(e9262)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Veccia A, Kinspergher S, Grego E,
Peterlana D, Berti A, Tranquillini E and Caffo O: Myositis and
myasthenia during nivolumab administration for advanced lung
cancer: A case report and review of the literature. Anticancer
Drugs. 31:540–544. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jeyakumar N, Etchegaray M, Henry J,
Lelenwa L, Zhao B, Segura A and Buja LM: The terrible triad of
checkpoint inhibition: A case report of myasthenia gravis,
myocarditis, and myositis induced by cemiplimab in a patient with
metastatic cutaneous squamous cell carcinoma. Case Reports Immunol.
2020(5126717)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Canino F, Pugliese G, Baldessari C, Greco
S, Depenni R and Dominici M: Cemiplimab- and nivolumab-induced
myasthenia gravis: Two clinical cases. Tumori. 107:NP123–NP126.
2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bawek SJ, Ton R, McGovern-Poore M,
Khoncarly B and Narvel R: Nivolumab-Induced myasthenia gravis
concomitant with myocarditis, myositis, and hepatitis. Cureus.
13(e18040)2021.PubMed/NCBI View Article : Google Scholar
|
